TheAnswerPage

MARCH 3, 2022

What is the most common qualifying condition reported by medical marijuana patients? Currently and historically the most common qualifying condition reported by medical marijuana patients is chronic pain. Qualifying Conditions of medical cannabis license holders in the United States. See the Answer.

Chronic Pain 59

Chronic Pain Conditions Data Patients 59

Veriheal

APRIL 23, 2024

By engaging individuals across various age groups and demographics, we gather insights into usage patterns, medical conditions, past substance experiences, and more. We have also used some information provided by New Frontier Data in 2022, which referenced various studies and findings on this age demographic’s substance use.

Chronic Pain 109

Chronic Pain Data Edibles Sleep 109

Veriheal

NOVEMBER 21, 2023

As we reflect on the success of the 2022 recipients, we are thrilled to introduce the exceptional winners of the 2023 scholarship. To alleviate this burden, we awarded $5,000 scholarships to five outstanding individuals in 2022. Veriheal recognizes the financial challenges students face in pursuing higher education.

Research and Development 106

Research and Development Consumption Education Data 106

Cannabis Law Report

SEPTEMBER 21, 2022

Reiterates Adjusted EBITDA Profitability Run Rate by December 31, 2022. Reaffirms $150 to $170 Million in Annualized Cost Savings by December 31, 2022. Million in Q4 2022. 20, 2022 /PRNewswire/ – Aurora Cannabis Inc. (the of Aurora’s Q4 2022 consolidated net revenue 1 and 86.3%

Research and Development 52

Research and Development Cannabis Data Events 52

Cannabis Law Report

SEPTEMBER 7, 2022

Since the legalisation of medical cannabis in the UK in 2018, there is little education surrounding medical cannabis and how it can help a large variety of conditions, should traditional medicine leave patients with an ‘unmet clinical need.’ .

Patients 52

Patients Conditions Treatment Education 52

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time. Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

JULY 25, 2022

million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). The data from this study is currently being assembled and MindBio is set to further announce the new findings. mentalhealth #help #lsd #menta … [link].

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

Veriheal

FEBRUARY 9, 2023

The data collected so far by the Turner Institute for Brain and Mental Health at Monash University in Australia suggests that psilocybin not only makes the process more comfortable but, as one participant described, MRIs become “magical.” All imaging and behavioral data will be accessible to the public after the study is complete.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Veriheal

JANUARY 26, 2023

Bipolar disorder is a complex condition that impacts millions worldwide, leading to extreme mood swings, intense emotional episodes, and difficulty managing day-to-day life. However, pharmaceutical medications can have side effects, and they may take longer to work for many patients.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

Cannabis Law Report

AUGUST 24, 2022

25 August 2022. The data suggests we have seen a transition from illicit to legal use of medical cannabis, ” said lead researcher Professor Nicholas Lintzeris , from the Faculty of Medicine and Health at the University of Sydney. People using illicit products were more likely to be treating mental health or sleep conditions.

Medicine 52

Medicine Legalization Chronic Pain Access 52

Cannabis Law Report

JANUARY 3, 2022

According to the amendment to the law on addictive substances and drugs, which came into force on January 1, doctors will now only prescribe medical marijuana to their patients electronically. Almost 200 doctors throughout the Czech Republic are currently prescribing therapeutic cannabis to some of their patients. Source: CTK.

Media 52

Media Chronic Pain Patients Treatment 52

Veriheal

JUNE 19, 2023

As of 2022, the global psychedelics market was valued at $4.87 All the data provided by the report are validated and trustworthy and can be used to gain the upper hand in the industry. In a study done in 2018 , when LSD was used alongside psychotherapy, patients experienced greater feelings of empathy, trust, and happiness.

Therapy 109

Therapy Treatment Patients Policy 109

Veriheal

DECEMBER 23, 2022

Dr. Maxwell’s team also collected data contained in samples sourced from California. After a close analysis of the data, the team determined that an absence of consistent federal guidelines regarding marijuana contaminants ultimately increases the risk of consumers developing health issues. 74 solvents. 21 microbes.

Research and Development 92

Research and Development Agriculture Data Extraction 92

Cannabis Law Report

MAY 10, 2022

11 May 2022. First academic study of national medicinal cannabis data. Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Veriheal

FEBRUARY 10, 2022

Medical cannabis patient enrollment is on the rise in South Dakota, and what better way to stay on top of things than by introducing a cloud-based platform? For the year 2022, patients who are interested in registering for South Dakota’s medical cannabis industry can apply with ease via the new fully digital internet-based program.

Programs 52

Programs Chronic Pain Patients Conditions 52

Cannabis Law Report

OCTOBER 22, 2021

Cybin’s Research and Development team has completed 74 in-vitro and in-vivo evaluations of Cybin’s expanding portfolio of psychedelic compounds being designed for potential therapeutic applications for several mental health conditions.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

MARCH 3, 2022

— Cannabis & Tech Today (@cannatechtoday) February 24, 2022. I’ve worked on this for so long that I know not only can it work, sometimes it’s the only thing that works for some of these conditions.”. “We link] #news #cannatechtoday #breaking #thc #florida #orlando #clinton #cbd #pain.

Media 52

Media CBD Events THC 52

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. ” In Vivo Toxicity Assays Completed. .

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

AUGUST 18, 2022

“We are at the beginning of a revolution in how mental health conditions are medically treated. Psychedelics present a new potential path to relief for patients who continue to struggle with mental health conditions despite conventional therapies,” he added. BUFFALO, N.Y. , Aug. Tweet this. ” Joining Ms.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

FEBRUARY 2, 2022

On January 25, 2022, the New York State Cannabis Control Board (CCB) held its fifth public meeting. During the meeting, Executive Director Chris Alexander announced the expansion of the medical cannabis program, including clinicians’ ability to certify patients for any clinical condition per their discretion.

Dispensary 52

Dispensary Retail Data Consumption 52

Cannabis Law Report

MARCH 8, 2022

DENVER) March 8, 2022 – Simplifya (“Simplifya” or “the Company”), the leading regulatory and operational compliance software platform serving the cannabis industry, announced the launch of its comprehensive suite of compliance solutions in New Mexico, expanding the company’s reach to 24 states.

Compliance 98

Compliance Compliance Research and Development Business 98

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Illinois News Joint

FEBRUARY 7, 2023

The Disparity and Availability Study’s purpose is to collect and analyze data and will report on whether discrimination exists in the Illinois cannabis industry. On February 14, 2022, the State published a formal request for proposals (RFP) to find a vendor to conduct a Disparity Study of the cannabis licensing system. Constitution.

Agriculture 81

Agriculture Cannabis Policy Dispensary 81

Cannabis Law Report

JULY 24, 2022

The legal framework regarding the use of psychedelics in patients is very pragmatic in Switzerland and unique internationally. Nevertheless, the regulatory hurdles for researchers and patients are still extremely high. A total of 170 patients were treated under these licenses. percent annually to $9.8 billion by 2029. [1]

Research and Development 52

Research and Development Legalization Treatment Patients 52

Cannabis Law Report

JUNE 8, 2022

Published: Jun 07, 2022. Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access. SAN JOSE, Calif. , June 7, 2022 /PRNewswire/ — MAPS Public Benefit Corp (MAPS PBC) today announced the appointment of Jeff George and Dan Grossman , Ph.D., He holds a Ph.D.

Therapy 52

Therapy Treatment Access Patients 52

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Fast Track review is for drugs that treat serious conditions and fill an unmet medical need.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Project CBD

JUNE 20, 2023

One gastrointestinal condition long associated with self-medication through cannabis is inflammatory bowel disease (IBD). In a newly published survey of 162 IBD patients in Puerto Rico, where medical cannabis is legal but recreational use is punishable with prison time , about 25% anonymously reported using cannabis to treat their symptoms.

Cannabinoids 208

Cannabinoids Patients Treatment Conditions 208

Cannabis Law Report

APRIL 6, 2022

Greenlight continues this path in medical cannabis to bring its patients not only the quality and consistency they desire, but a unique experience that will keep them coming in. Agrify’s Stackable Cultivation Solutions Will Double Canopy for Prominent Multi-State Operator. BILLERICA, Mass., About Agrify (Nasdaq:AGFY).

Extraction 52

Extraction Cultivation Seed-To-Sale Events 52

Freedom Leaf

OCTOBER 15, 2018

Frontier Data predicts total sales of all CBD products in the U.S. billion by 2022. Frontier Data predicts total sales of all CBD products in the U.S. billion by 2022. A month later, on May 16, the Department of Health and Human Services approved the FDA’s Epidiolex recommendation. will top $1.9 John’s wort. will top $1.9

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

AUGUST 4, 2021

We thus provide comparison with the pre-pandemic period of H1 2019 as an additional data point. At the time of FY 2020 results publication, we estimated that EUR 250m revenues had been lost in FY 2020 due to the impact of COVID-19 lockdowns and travel restrictions and the objective was to recover these revenues by 2022.

Business 105

Business Research and Development Environment Food 105

Veriheal

JANUARY 5, 2022

Despite the restrictions on research as a result of the Schedule I classification of cannabis, researchers have made many remarkable strides in proving the efficacy and safety of cannabis on the aforementioned conditions. . While Biden is receiving a lot of heat as a result of his inaction, many feel it is deserved.

Legislation 52

Legislation Cannabis Therapy Access 52

Cannabis Law Report

OCTOBER 29, 2021

NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. We expect to report this data as it becomes available and after submission to the FDA. .–(BUSINESS WIRE)– #Alzheimers –India Globalization Capital, Inc.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

MAY 19, 2022

FDA states it has received 104 reports of adverse events in patients who consumed delta-8 THC products between December 1, 2020 and February 28, 2022. Many CBD users have reported improvements in: Stress; Anxiety; Sleep; Pain levels; Skin conditions including acne and eczema; Epilepsy”. FDA Warning Letters. Moving Forward.

THC 52

THC CBD Food Pets 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Project CBD

FEBRUARY 27, 2023

Instead, patients turn to a mix of whatever individual medications, therapies, and lifestyle changes (especially exercise) help ease symptoms and improve quality of life. “Available data strongly support the use of cannabinoids in treating fibromyalgia pain” due to “overwhelmingly positive treatment results.”

THC 144

THC CBD Sleep Clinical Trials 144

Veriheal

OCTOBER 3, 2022

With the growing acceptance and legalization of cannabis, the pharmaceutical industry is taking serious hits, according to a 2022 novel study into the impact of cannabis legalization on pharmaceutical firms. The team that conducted the study looked at stock return and prescription drug sales data for 556 pharmaceutical companies.

Pharmaceutical 104

Pharmaceutical Patients Research and Development Legalization 104

CannaTech

OCTOBER 14, 2018

Similar conditions in the Imperial Valley of extreme southern California have permitted cultivators like Farmtiva to thrive as the company operates an industrial hemp research and grow facility on 160 acres of a former U.S. billion by 2022, according to New Frontier Data, a premier cannabis data analytics firm.

Hemp 53

Hemp Research and Development Agriculture Seed-To-Sale 53